A 7-gene signature of the recipient predicts the progression of fibrosis after liver transplantation for hepatitis C virus infection

Liver Transplantation

Volumn 18, Issue 3, 2012, Pages 298-304

  Do O, Nicole T ^a   Eurich, Dennis ^b   Schmitz, Petra ^a   Schmeding, Maximilian ^a,b   Heidenhain, Christoph ^a,b   Bahra, Marcus ^b   Trautwein, Christian ^a   Neuhaus, Peter ^b   Neumann, Ulf P ^a,b   Wasmuth, Hermann E ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; ADAPTOR RELATED PROTEIN COMPLEX 3 S2; ANTIZYME; ANTIZYME INHIBITOR 1; AQUAPORIN 2; BINDING PROTEIN; DEGENERATIVE SPERMATOCYTE HOMOLOG 1 LIPID DESATURASE; OXYGENASE; SYNTAXIN BINDING PROTEIN 5 LIKE; TOLL LIKE RECEPTOR 4; TRANSIENT RECEPTOR POTENTIAL CHANNEL M5; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; ADULT; AGED; ALLELE; ARTICLE; CIRRHOSIS RISK SCORE; DISEASE COURSE; DISEASE SEVERITY; FEMALE; FOLLOW UP; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GRAFT INFECTION; GRAFT RECIPIENT; HEPATITIS C; HUMAN; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS; RECURRENT INFECTION; REINFECTION; RISK ASSESSMENT;

ADULT; AGED; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION PROFILING; HEPATITIS C; HUMANS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; RECURRENCE;

EID: 84857541085     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.22475     Document Type: Article

References (39)

1. Wiesner RH, Sorrell M, Villamil F,; for International Liver Transplantation Society Expert Panel. Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl 2003; 9: S1-S9. (Pubitemid 37407996)
2. Neumann UP, Berg T, Bahra M, Puhl G, Guckelberger O, Langrehr JM, Neuhaus P,. Long-term outcome of liver transplants for chronic hepatitis C: a 10-year follow-up. Transplantation 2004; 77: 226-231. (Pubitemid 38155751)
3. Watt K, Veldt B, Charlton M,. A practical guide to the management of HCV infection following liver transplantation. Am J Transplant 2009; 9: 1707-1713.
4. Gane EJ, Portmann BC, Naoumov NV, Smith HM, Underhill JA, Donaldson PT, et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996; 334: 815-820. (Pubitemid 26099603)
5. Bahra M, Neumann UP, Jacob D, Langrehr JM, Berg T, Neuhaus R, Neuhaus P,. Fibrosis progression in hepatitis C positive liver recipients after sustained virologic response to antiviral combination therapy (interferon-ribavirin therapy). Transplantation 2007; 83: 351-353.
6. Gallegos-Orozco JF, Yosephy A, Noble B, Aqel BA, Byrne TJ, Carey EJ, et al. Natural history of post-liver transplantation hepatitis C: a review of factors that may influence its course. Liver Transpl 2009; 15: 1872-1881.
7. Mallat A, Hezode C, Lotersztajn S,. Environmental factors as disease accelerators during chronic hepatitis C. J Hepatol 2008; 48: 657-665.
8. Weber SN, Wasmuth HE,. Liver fibrosis: from animal models to mapping of human risk variants. Best Pract Res Clin Gastroenterol 2010; 24: 635-646.
9. Osterreicher CH, Stickel F, Brenner DA,. Genomics of liver fibrosis and cirrhosis. Semin Liver Dis 2007; 27: 28-43.
10. Wali M, Harrison RF, Gow PJ, Mutimer D,. Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C. Gut 2002; 51: 248-252. (Pubitemid 34791456)
11. Roche B, Samuel D,. Risk factors for hepatitis C recurrence after liver transplantation. J Viral Hepat 2007; 14 (suppl 1): 89-96. (Pubitemid 47624117)
12. Langrehr JM, Puhl G, Bahra M, Schmeding M, Spinelli A, Berg T, et al. Influence of donor/recipient HLA-matching on outcome and recurrence of hepatitis C after liver transplantation. Liver Transpl 2006; 12: 644-651.
13. Berres ML, Trautwein C, Schmeding M, Eurich D, Tacke F, Bahra M, et al. Serum chemokine CXC ligand 10 (CXCL10) predicts fibrosis progression after liver transplantation for hepatitis C infection. Hepatology 2011; 53: 596-603.
14. Micheloud D, Salcedo M, Bañares R, Rincõn D, Lorente R, Muñoz-Fernández MA, Resino S,. Serum levels of fibrosis biomarkers measured early after liver transplantation are associated with severe hepatitis C virus recurrence. Transpl Infect Dis 2009; 11: 183-188.
15. Dhillon N, Walsh L, Krüger B, Ward SC, Godbold JH, Radwan M, et al. A single nucleotide polymorphism of toll-like receptor 4 identifies the risk of developing graft failure after liver transplantation. J Hepatol 2010; 53: 67-72.
16. Buis CI, van der Steege G, Visser DS, Nolte IM, Hepkema BG, Nijsten M, et al. Heme oxygenase-1 genotype of the donor is associated with graft survival after liver transplantation. Am J Transplant 2008; 8: 377-385.
17. Falleti E, Fabris C, Toniutto P, Fontanini E, Cussigh A, Caldato M, et al. Genetic polymorphisms of inflammatory cytokines and liver fibrosis progression due to recurrent hepatitis C. J Interferon Cytokine Res 2007; 27: 239-246. (Pubitemid 46435492)
18. Toniutto P, Fabris C, Falleti E, Cussigh A, Fontanini E, Bitetto D, et al. Methylenetetrahydrofolate reductase C677T polymorphism and liver fibrosis progression in patients with recurrent hepatitis C. Liver Int 2008; 28: 257-263. (Pubitemid 351201039)
19. Fabris C, Toniutto P, Bitetto D, Minisini R, Smirne C, Caldato M, Pirisi M,. Low fibrosis progression of recurrent hepatitis C in apolipoprotein E Ïμ4 carriers: relationship with the blood lipid profile. Liver Int 2005; 25: 1128-1135. (Pubitemid 41782555)
20. Ben-Ari Z, Pappo O, Druzd T, Sulkes J, Klein T, Samra Z, et al. Role of cytokine gene polymorphism and hepatic transforming growth factor β1 expression in recurrent hepatitis C after liver transplantation. Cytokine 2004; 27: 7-14. (Pubitemid 38780932)
21. Ben-Ari Z, Tambur AR, Pappo O, Sulkes J, Pravica V, Hutchinson I, et al. Platelet-derived growth factor gene polymorphism in recurrent hepatitis C infection after liver transplantation. Transplantation 2006; 81: 392-397. (Pubitemid 43255725)
22. Charlton MR, Thompson A, Veldt BJ, Watt K, Tillmann H, Poterucha JJ, et al. Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection. Hepatology 2011; 53: 317-324.
23. Eurich D, Boas-Knoop S, Ruehl M, Schulz M, Carrillo ED, Berg T, et al. Relationship between the interleukin-28b gene polymorphism and the histological severity of hepatitis C virus-induced graft inflammation and the response to antiviral therapy after liver transplantation. Liver Transpl 2011; 17: 289-298.
24. Bataller R, North KE, Brenner DA,. Genetic polymorphisms and the progression of liver fibrosis: a critical appraisal. Hepatology 2003; 37: 493-503. (Pubitemid 36258768)
25. Manolio TA,. Genomewide association studies and assessment of the risk of disease. N Engl J Med 2010; 363: 166-176.
26. Huang H, Shiffman ML, Friedman S, Venkatesh R, Bzowej N, Abar OT, et al. A 7 gene signature identifies the risk of developing cirrhosis in patients with chronic hepatitis C. Hepatology 2007; 46: 297-306. (Pubitemid 47344763)
27. Marcolongo M, Young B, Dal Pero F, Fattovich G, Peraro L, Guido M, et al. A seven-gene signature (cirrhosis risk score) predicts liver fibrosis progression in patients with initially mild chronic hepatitis C. Hepatology 2009; 50: 1038-1044.
28. Trépo E, Potthoff A, Pradat P, Bakshi R, Young B, Lagier R, et al. Role of a cirrhosis risk score for the early prediction of fibrosis progression in hepatitis C patients with minimal liver disease. J Hepatol 2011; 55: 38-44.
29. Wasmuth HE, Trautwein C,. Prediction of fibrosis progression in hepatitis C infection: are genetics ready for clinical use? J Hepatol 2011; 55: 3-4.
30. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ,. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994; 19: 1513-1520. (Pubitemid 24166476)
31. Schulz KF, Grimes DA,. Case-control studies: research in reverse. Lancet 2002; 359: 431-434. (Pubitemid 34158958)
32. Guo J, Loke J, Zheng F, Hong F, Yea S, Fukata M, et al. Functional linkage of cirrhosis-predictive single nucleotide polymorphisms of toll-like receptor 4 to hepatic stellate cell responses. Hepatology 2009; 49: 960-968.
33. Seki E, De Minicis S, Osterreicher CH, Kluwe J, Osawa Y, Brenner DA, Schwabe RF,. TLR4 enhances TGF-β signaling and hepatic fibrosis. Nat Med 2007; 13: 1324-1332. (Pubitemid 350073596)
34. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461: 798-801.
35. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
36. Abe H, Ochi H, Maekawa T, Hayes CN, Tsuge M, Miki D, et al. Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients. J Hepatol 2010; 53: 439-443.
37. McCarthy MI, Abecasis GR, Cardon LR, Goldstein DB, Little J, Ioannidis JP, Hirschhorn JN,. Genome-wide association studies for complex traits: consensus, uncertainty and challenges. Nat Rev Genet 2008; 9: 356-369. (Pubitemid 351556063)
38. Hardy J, Singleton A,. Genomewide association studies and human disease. N Engl J Med 2009; 360: 1759-1768.
39. Ghiassi-Nejad Z, Friedman SL,. Advances in antifibrotic therapy. Expert Rev Gastroenterol Hepatol 2008; 2: 803-816.